Top Wall Street Forecasters Revamp Eli Lilly Expectations Ahead Of Q3 Earnings
Eli Lilly reports Q3 earnings Oct. 29; EPS is forecast at $6.67, revenue at $22.62B. New Omvoh data supports ulcerative colitis and Crohn’s treatment.
Share
Why It Matters
Smart money people changed their guesses about Eli Lilly before earnings. They see promise in a new medicine for gut problems.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.